Pretreatment Out-of-Pocket Expenses for Presumptive Multidrug-Resistant Tuberculosis Patients, India, 2016 –2017

P. Rathi et al.
Source: Emerging Infectious Diseases Journal - Category: Infectious Diseases Source Type: research

Related Links:

Multidrug- and rifampicin-resistant tuberculosis (MDR-/RR-TB) have evolved into a global public health crisis. In late 2019, the World Health Organization (WHO) issued a rapid communication [1] advising national TB programmes to phase out the injectable-containing shorter regimen. WHO indicated that the preferred treatment option is a shorter, all-oral, bedaquiline-containing regimen and emphasised that "access to rapid drug susceptibility testing, especially for ruling out fluoroquinolone resistance, is required" before starting the bedaquiline-containing shorter regimen [1].
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Original Articles: Correspondence Source Type: research
In this study, we analyzed the distribution of Mycobacterium species, compare the diagnostic methods, and susceptibilities to anti-tuberculosis drugs of TB isolates. The aim was to document the current status and to provide a frame of reference for future studies. In this study, 278 Mycobacterium species isolated from 7,480 patients between September 2015 and June 2019 were included. Löwenstein-Jensen medium (LJ) and MGIT 960 were used for the isolation of strains. Susceptibility to 1st-line anti-tuberculosis drugs was determined. Positivity rates in clinical samples were as follows: 1.4% for direct microscopic acid-f...
Source: Polish Journal of Microbiology - Category: Microbiology Tags: Pol J Microbiol Source Type: research
CONCLUSIONS: Body mass index and population density were inversely associated with pulmonary tuberculosis relapses in Cali. On the contrary, alcohol consumption increased the likelihood of tuberculosis relapses. PMID: 32463612 [PubMed - as supplied by publisher]
Source: Biomedica : Revista del Instituto Nacional de Salud - Category: International Medicine & Public Health Tags: Biomedica Source Type: research
AbstractPretomanid, a nitroimidazoxazine antimycobacterial agent, presents a valuable option for the treatment of adults with pulmonary extensively drug-resistant (XDR) tuberculosis (TB) or treatment-intolerant or nonresponsive multidrug-resistant (MDR)-TB when used as part of an all-oral combination regimen with bedaquiline and linezolid. In the pivotal phase  III Nix-TB trial, a combination regimen of pretomanid, bedaquiline, and linezolid for 6 months had a high treatment success rate. Besides the demonstrated effectiveness, the pretomanid, bedaquiline, and linezolid combination has other benefits, including t...
Source: Drugs and Therapy Perspectives - Category: Drugs & Pharmacology Source Type: research
NEW BRUNSWICK, NJ, May 27, 2020— The Janssen Pharmaceutical Companies of Johnson&Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a new pediatric formulation of Sirturo (bedaquiline)....
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
The world strives for progress towards accelerating the decline rate of tuberculosis (TB) incidence from 2% to 10% per year to reach the 2035 milestone of the End TB Strategy (WHO 2014). However, the appearance and growing incidence of drug-resistant TB impedes this progress largely. WHO estimated that in 2018, there were 484000 new cases with resistance to rifampicin (the most effective first-line drug) and 78% of these cases were multidrug-resistant TB (MDR-TB) (WHO 2019). Early and accurate diagnosis is of utmost importance to mitigate burden brought by MDR-TB (WHO 2010).
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Source Type: research
NEW BRUNSWICK, NJ, May 27, 2020 — The Janssen Pharmaceutical Companies of Johnson &Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a new pediatric formulation of SIRTURO® (bedaquiline). SIRTURO® is now indicated for use as part of combination therapy in the treatment of adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary multidrug-resistant tuberculosis (MDR‑TB). In the U.S., the medicine should be reserved for use when an effective treatment regimen cannot otherwise be provided. This indication received accelera...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
ConclusionsDiscovery delay for an index patient played a primary role in MDR-TB transmission inside the school. To immediately detect TB, morning examinations in schools should be performed. TB trackers and case managers should work closely with public health workers and physicians in cases of TB outbreaks or transmissions involving students. Moreover, individuals who are in close contact with MDR-TB patients should undergo careful clinical follow-up for at least two  years. Implementing a joint examination strategy to ensure early detection, diagnosis, and treatment of MDR-TB transmission is recommended.
Source: Infectious Diseases of Poverty - Category: Infectious Diseases Source Type: research
Authors: Rodrigues L, Cravo P, Viveiros M Abstract Introduction: In 2018, an estimated 377,000 people developed multidrug-resistant tuberculosis (MDR-TB), urging for new effective treatments. In the last years, it has been accepted that efflux pumps play an important role in the evolution of drug resistance. Strategies are required to mitigate the consequences of the activity of efflux pumps.Areas covered: Based upon the literature available in PubMed, up to February 2020, on the diversity of efflux pumps in Mycobacterium tuberculosis and their association with drug resistance, studies that identified efflux inhibi...
Source: Expert Review of Anti-Infective Therapy - Category: Infectious Diseases Tags: Expert Rev Anti Infect Ther Source Type: research
Condition:   Multi-Drug Resistant Tuberculosis Intervention:   Sponsor:   Assistance Publique - Hôpitaux de Paris Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: India Health | Infectious Diseases | Multidrug Resistance | Tuberculosis